Harrow, Inc. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Harrow, Inc. (HROW) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 27.48 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2021-05-11
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2021-03-31 was 27.48M shares, a 6.24% increase year-over-year.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2020-09-30 was 27.09M shares, a 5.89% increase year-over-year.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2020-06-30 was 25.89M shares, a 2.68% increase year-over-year.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2020-03-31 was 25.87M shares, a 2.72% decline year-over-year.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2019 was 26.47M shares, a 11.15% increase from fiscal 2018.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2018 was 23.81M shares, a 18.90% increase from fiscal 2017.
- Harrow, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2017 was 20.03M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 6 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|---|---|---|
| 2021-03-31 | 27.48M shares 10-Q · filed 2021-05-11 | |||
| 2020-09-30 | 27.09M shares 10-Q · filed 2020-11-09 | 25.88M shares 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | 25.89M shares 10-Q · filed 2020-08-10 | 25.87M shares 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | 25.87M shares 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | 26.47M shares 10-K · filed 2021-03-08 | |||
| 2019-09-30 | 25.58M shares 10-Q · filed 2020-11-09 | 25.21M shares 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 25.22M shares 10-Q · filed 2020-08-10 | 26.70M shares 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 26.59M shares 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | 23.81M shares 10-K · filed 2020-03-13 | |||
| 2018-06-30 | 23.18M shares 10-Q · filed 2019-08-14 | 21.07M shares 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | 20.95M shares 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | 20.03M shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |